Portfoliotracker

PepGen Inc.

PEPG · NASDAQGS · Healthcare Biotechnology 6/100 E

4,190 $
▼ −0,170 (−3,90 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:28
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score6 / 100 Market cap290 mil. $ P/E– Forward P/E-3,7 P/S– P/B2,8 EV/EBITDA– Dividend yield– FCF yield-21,81 % EPS-0,77 $ Net margin0,0 % Return on equity-55,1 % Beta– Debt / equity0,15
52-week range 1,31 to 7,80
3-month average volume3,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Website
pepgen.com
Employees
56
Country
United States
Fiscal year end
31. 12.
Data since
6. 5. 2022

Explore further

Similar companies GLUEMLYSTYRAEWTX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account